International Foundation for Optic Nerve Disease

Mitochondrial genome editing
An article in Nature published on 8 July 2020 describes a breakthrough in editing mitochondrial DNA analogous to CRISPR technology for editing nuclear DNA. This opens research paths for mitochondrial diseases.

References:

Mok, B.Y., de Moraes, M.H., Zeng, J. et al. A bacterial cytidine deaminase toxin enables CRISPR-free mitochondrial base editing. Nature 583, 631–637 (2020). https://doi.org/10.1038/s41586-020-2477-4

Magomet Aushev & Mary Herbert. Mitochondrial genome editing gets precise A bacterial toxin has been found that allows DNA in a cellular organelle called the mitochondrion to be precisely altered. This development could help to combat diseases caused by mutations in mitochondrial DNA. https://www.nature.com/articles/d41586-020-01974-6

The International Foundation for Optic Nerve Disease
P. O. Box 777, Cornwall NY 12518, USA.
Phone/Fax: (845)5348606
Email: ifond@aol.com
Web site: http://www.ifond.org/

IFOND is registered service mark of The International Foundation for Optic Nerve Disease, est. October 1995.

Copyright 1999-2024, International Foundation for Optic Nerve Disease.

The information contained on this website should not be considered medical guidance or professional advice. IFOND is not responsible for errors or omissions in information provided on this site or actions resulting from its use. IFOND does not publish all information from all available sources on optic nerve disease. IFOND is not responsible for the validity of the studies or reviews nor is it an advocate of studies or reviews mentioned on or linked from the IFOND web site. IFOND does not endorse or recommend participation in any particular clinical trial or treatment protocol which may be mentioned on this site. Direct any questions concerning your personal health to your appropriate health care professional.